Caris to Integrate Molecular Testing with Flatiron Health’s OncoEMR

Credit: NicoElNino/Getty Images

Molecular testing company Caris Life Sciences today announced a partnership with cancer-focused technology company Flatiron Health to integrate the ordering and delivery of its oncology molecular test results with Flatiron’s OncoEMR, an electronic medical record based on the cloud.

By integrating with OncoEMR, Caris will extend the reach of its molecular profiling product portfolio to more than 2,000 clinicians in Flatiron Health’s operating network of more than 800 cancer care centers across the United States.

“The integration with OncoEMR is another important step in our goal of making personalized precision healthcare accessible to as many physicians and patients as possible,” said David Spetzler, President and CSO of Caris. “Providing critical molecular results directly at the point of care in community oncology facilities is paramount to every patient’s ability to fight and hopefully beat cancer. Integration into the OncoEMR platform, which reaches nearly 40% of all US community oncologists, helps us significantly in delivering on our commitment. »

Once the integration is complete, users will be able to order Caris testing services directly from OncoEMR. It will also track orders and deliver test results directly to the cloud-based platform. The integration of molecular results solves a persistent problem in healthcare, that of providing clinicians with direct access to patient-specific genomic data in the same environment that clinicians use to develop patient care plans, which could save clinicians valuable time. Flatiron will make the integration with Caris available to all its oncology practices in the network who want it for free.

“Understanding tumor biology enables precision medicine, and this integration of molecular profiling with Caris allows oncologists and their teams to efficiently order molecular profiling tests, track order status, and view results. , all without leaving OncoEMR,” said James Hamrick, Vice President of Clinical Oncology at Flatiron Health. “Simplifying the workflow can support appropriate and fair testing, eliminate redundant testing, minimize disruption to practice, and uncover therapeutic opportunities with the goal of achieving better patient outcomes.”

The integration constitutes Caris’ entire portfolio of molecular profiling services, including whole exome and whole transcriptome sequencing on OncoEMR, and the company notes that it is the only company to integrate this service into the flatiron tool.

Caris said it will continue to work with EMR providers to find new ways to integrate its molecular profiling information directly into electronic patient records to improve patient care and education.

In June this year, Caris announced that it would integrate its testing portfolio into market leader Epic’s ORA (Orders and Results Anywhere) network. This follows an earlier integration of the Epic Genomics module. Caris has also completed similar integrations with EMR vendors MEDITECH, Cerner and Practice Fusion, among others.

Add Comment